---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-015284"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:36:36.685223+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ENDRA Q3 net loss $3.4M; cash $8.0M; 95 TAEUS scans YTD, De Novo submission near

## Summary
- Net loss $3.4 million ($0.05 per share) vs $2.7 million loss ($0.06) in Q3 2021.
- Cash and equivalents $8.0 million as of Sept 30, 2022; operating expenses rose to $3.4M from $2.7M.
- Nearly doubled TAEUS scans to 95 YTD; collecting final data for FDA De Novo submission for liver device.
- Expanded IP portfolio to 56 issued patents; eight new patents added in Q3.
- Management reiterates cash sufficient to fund through key milestones including European commercialization and U.S. regulatory submission.

## SEC filing metadata
- accession: 0001654954-22-015284
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495422015284/0001654954-22-015284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495422015284/endra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-015284
- JSON: https://secwatch.observer/filing/0001654954-22-015284.json
- Plain text: https://secwatch.observer/filing/0001654954-22-015284.txt

## Key facts
- Earnings Releases
  ENDRA Life Sciences Inc. reported third quarter of 2022 results: net income $3.4 million, EPS $0.05 per share.
  - Period: third quarter of 2022
  - Net income: $3.4 million
  - EPS: $0.05 per share
  - Result: reported results
  source text: Net loss in the third quarter of 2022 was $3.4 million, or $0.05 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495422015284/0001654954-22-015284-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.